Dupixent (Dupilumab)

Dupixent (dupilumab) is an interleukin-4 receptor alpha antagonist used:

• Atopic Dermatitis: for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. This medicine can be used with or without topical corticosteroids.
• Asthma: as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid-dependent asthma. It is not for the relief of acute bronchospasm or status asthmaticus.
• Chronic Rhinosinusitis with Nasal Polyps: as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
• Eosinophilic Esophagitis: for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE).
• Prurigo Nodularis: for the treatment of adult patients with prurigo nodularis (PN).
• Chronic Obstructive Pulmonary Disease: as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. This therapeutic drug is not for the relief of acute bronchospasm.
• Chronic Spontaneous Urticaria: for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. Do not use Dupilumab in other forms of urticaria.

Recommended Dosage: The recommended dosage of Dupixent is administered by subcutaneous (SC) injection. Administer the injection into the thigh or abdomen, except for the 2 inches (5 cm) around the navel. The upper arm can also be used in case a caregiver administers the injection. Rotate the site of the injection with each injection. It is not advisable to inject the injection into skin that is tender, damaged, bruised, or scarred.
Recommended Dosage for Atopic Dermatitis:
Dosage in Adults: The recommended dosage is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every 2 weeks (Q2W).

Dosage in Pediatric Patients Aged 6 Months to 5 Years: The recommended dosage depends on their body weight. For children weighing 5 kg to less than 15 kg, the initial and subsequent dosage is 200 mg (one 200 mg injection) administered every 4 weeks. For children weighing 15 to less than 30 kg, the dosage increases to 300 mg (one 300 mg injection) every 4 weeks.

Dosage in Pediatric Patients Aged 6 Years to 17 Years: The recommended dosage is also based on body weight. For those weighing 15 to less than 30 kg, the initial loading dose is 600 mg (two 300 mg injections), followed by 300 mg every 4 weeks. For children weighing 30 to less than 60 kg, the initial loading dose is 400 mg (two 200 mg injections), with subsequent dosages of 200 mg every 2 weeks. For children weighing 60 kg or more, the dosage remains at 600 mg (two 300 mg injections) initially, followed by 300 mg every 2 weeks.

Recommended Dosage for Asthma:
Dosage in Adult and Pediatric Patients 12 Years and Older: The recommended initial loading dose is either 400 mg (two 200 mg injections) or 600 mg (two 300 mg injections), followed by 200 mg every 2 weeks. For patients with oral corticosteroid-dependent asthma or moderate-to-severe atopic dermatitis with co-morbid chronic rhinosinusitis with nasal polyps, the dosage is 600 mg (two 300 mg injections) followed by 300 mg every 2 weeks.
Dosage in Pediatric Patients 6 to 11 Years of Age: The recommended dosage depends on body weight. For those weighing 15 to less than 30 kg, the initial dose is 300 mg every 4 weeks, followed by 300 mg every 4 weeks. For those weighing 30 kg or more, the initial and subsequent dosage is 200 mg every 2 weeks.

Recommended Dosage for Chronic Rhinosinusitis with Nasal Polyps: The recommended dosage for adult and pediatric patients aged 12 years and older is 300 mg administered every 2 weeks (Q2W).

Recommended Dosage for Eosinophilic Esophagitis: For adult and pediatric patients 1 year of age and older with Eosinophilic Esophagitis and weighing at least 15 kg, the recommended dosage is as follows:

• For patients weighing 15 to less than 30 kg, the dosage is 200 mg every 2 weeks.
• For patients weighing 30 to less than 40 kg, the dosage is 300 mg every 2 weeks.
• For patients weighing 40 kg or more, the dosage is 300 mg every week.

Recommended Dosage for Prurigo Nodularis: The recommended dosage for adult patients is an initial dose of 600 mg (two 300 mg injections) followed by 300 mg administered every 2 weeks (Q2W).

Recommended Dosage for Chronic Obstructive Pulmonary Disease: The recommended dosage for adult patients is 300 mg administered every 2 weeks (Q2W).

Recommended Dosage for Chronic Spontaneous Urticaria:

• Dosage in Adults: The recommended dosage for adult patients is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg administered every 2 weeks (Q2W).
• Dosage in Pediatric Patients Aged 12 to 17 Years: The recommended dosage depends on body weight. For those weighing 30 to less than 60 kg, the initial loading dose is 400 mg (two 200 mg injections), followed by 200 mg every 2 weeks. For patients weighing 60 kg or more, the initial loading dose is 600 mg (two 300 mg injections), followed by 300 mg every 2 weeks.

• Treatment with Dupilumab 200 mg/ 300 mg injection could cause hypersensitivity reactions. Look for rashes, swelling, or any breathing complications. If any symptoms arise, discontinue the treatment and get immediate medical care.
• Eye issues like inflammation of the eye (conjunctivitis) or corneal inflammation (keratitis) could be caused by this therapeutic drug. Notify your physician if eye pain, redness, or vision changes are noticed.
• This therapeutic drug can result in higher eosinophils in the blood. Monitor any pulmonary symptoms with shortness of breath, wheezing, or chest pain. If any symptoms related to eosinophilic conditions appear, stop the medication.
• When using this medicinal product, the corticosteroid dosage may be reduced gradually. Do not stop corticosteroids all of a sudden. Consult your healthcare provider (HCP) for appropriate dosage adjustments to prevent adrenal insufficiency.
• With this treatment, existing cases of psoriasis may get worse, or new cases may come up as well. In case of skin lesions, redness, or irritation of the skin, report to your healthcare provider (HCP) for better assessment and management.
• There are reports of a few patients complaining about joint pain (Arthralgia) or developing psoriatic arthritis. When there is pain/stiffness in the joints, report to a health professional for an appropriate change in treatment.
• When prescribed this therapeutic drug, the chance of getting infected with parasites could go up. Make sure there is an appropriate diagnosis and intervention for any parasitic infection that may be there. If one experiences fever, abdominal pain, or swelling, do seek medical care.
• Before starting Dupilumab 200 mg/ 300 mg injection, all vaccinations should be completed. Patients on this therapy should not have live vaccinations. Other non-live vaccinations can be given, but check with your healthcare practitioner (HCP) prior.
• This medicine should be used with caution during pregnancy. Administering during pregnancy increases the risks. It is unclear if the drug is excreted in milk. Speak to your doctor regarding its use during pregnancy or nursing.

What documents are required to import DUPIXENT to India?

DUPIXENT (dupilumab) injections can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?
The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is DUPIXENT available in India?

Dupixent (dupilumab injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Dupixent in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

DUPIXENT can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of DUPIXENT (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Dupixent 200 mg/300 mg injection price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source DUPIXENT (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Dupixent®?

Dupilumab is a Generic Name for the trade name drug Dupixent®.

What is the Manufacturer's Name of Dupixent®?

Dupixent® is manufactured by Regeneron Pharmaceuticals, Inc.

Is Dupixent approved by the FDA?

Yes, Dupixent® is approved by the FDA. Date of first approval: March 28, 2017.

What is the dosage and form of Dupixent® supplied?

Dupixent® is supplied in the following forms for subcutaneous (SC) use:

• Injection: 300 mg/2 mL and 200 mg/1.14 mL in single-dose pre-filled syringes with needle shield.
• Injection: 300 mg/2 mL and 200 mg/1.14 mL in single-dose pre-filled pens.

What are the most common side effects of Dupixent® 300 mg/200 mg injections?

The most common side effects of Dupixent® injection are:

• Atopic Dermatitis: oral herpes, injection site reactions, conjunctivitis, blepharitis, keratitis, eye pruritus, other herpes simplex virus infections, dry eye, and eosinophilia.
• Asthma: oropharyngeal pain, injection site reactions, and eosinophilia.
• Chronic Rhinosinusitis with Nasal Polyps: eosinophilia, insomnia, injection site reactions, toothache, arthralgia, gastritis, and conjunctivitis.
• Eosinophilic Esophagitis: upper respiratory tract infections, injection site reactions, arthralgia, and herpes viral infections.
  Prurigo Nodularis: nasopharyngitis, herpes infection, conjunctivitis, dizziness, myalgia, and diarrhea.
• Chronic Obstructive Pulmonary Disease: back pain, viral infection, headache, nasopharyngitis, diarrhea, rhinitis, arthralgia, toothache, urinary tract infection, local administration reactions, eosinophilia, and gastritis.
• Chronic Spontaneous Urticaria: injection site reactions.

How much does Dupixent® 300 mg/200 mg injection cost in India?

Prices of Dupixent injections may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Dupixent 300 mg 200 mg injection cost in India, please Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Dupixent® 300 mg/200 mg injections be available in SAARC countries?

Apart from Gulf countries, Dupixent® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Dupixent® injections in these countries. We help ensure legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Dupixent® 300 mg/200 mg injections online in India?

Yes, one can buy Dupixent 300 mg-200 mg online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Dupixent® injections through legal channels.

What are the storage conditions of Dupixent® 300 mg/200 mg injections?

Store refrigerated this therapeutic drug at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. If necessary, it may be kept at room temperature up to 25°C (77°F) for a maximum of 14 days. Avoid storing it above 25°C (77°F).